Search results
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
Investor's Business Daily· 3 hours agoPTC stock hit a nine-month high Monday after the European Commission decided against pulling its...
Kentucky Retirement Systems Decreases Stock Holdings in PTC Inc. (NASDAQ:PTC)
ETF DAILY NEWS· 14 hours agoKentucky Retirement Systems lessened its holdings in PTC Inc. (NASDAQ:PTC – Free Report) by 4.6% during the 4th quarter, according to its most recent disclosure ...
EC withholds negative stance on Translarna in Europe By Investing.com
Investing.com· 8 hours agoPTC Therapeutics, Inc. (NASDAQ: NASDAQ:PTCT) disclosed on Monday that the European Commission (EC)...
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Raymond James
ETF DAILY NEWS· 13 hours agoPTC Therapeutics (NASDAQ:PTCT – Get Free Report) was upgraded by Raymond James from an “underperform” rating to a “market perform” rating in a research report issued on Monday ...
PTC Therapeutics stock target raised on re-evaluation of Translarna By Investing.com
Investing.com· 6 hours agoOn Monday, Jefferies maintained a Buy rating on PTC Therapeutics (NASDAQ:PTCT) and increased the...
PTCT stock target raised, maintains sell rating on favorable regulatory development By Investing.com
Investing.com· 4 hours agoOn Monday, Goldman Sachs updated its view on PTC Therapeutics shares (NASDAQ:PTCT), raising the...
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
BioPharma Dive via Yahoo Finance· 11 hours agoRather than endorse the recommendation of the EMA, the commission called for a new review for...
PTC Therapeutics Pauses 2024 Revenue Guidance After European Commission Requests Reevaluation of...
Market Watch· 11 hours agoPTC Therapeutics has paused its 2024 revenue guidance after the European Commission decided against adopting a committee's negative opinion on the annual renewal of Translarna's ...
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
FOX 23 News Albany· 6 days agoPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the...
PTC stock rated an Overweight by JP Morgan – Knox Daily
Knox Daily· 7 days agoPTC Inc’s recently made public that its Director Lathan Corinna unloaded Company’s shares for reported $0.34 million on May 09 ’24. In the deal valued at $179.39 per share ...